Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
1860 | 2454 | 51.0 | 94% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
304 | 3 | P53//RETINOBLASTOMA//MDM2 | 40663 |
936 | 2 | P53//MDM2//P73 | 10991 |
1860 | 1 | MDM2//MDMX//MDM4 | 2454 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | MDM2 | authKW | 2875951 | 25% | 38% | 609 |
2 | MDMX | authKW | 1219435 | 4% | 91% | 108 |
3 | MDM4 | authKW | 590394 | 3% | 77% | 62 |
4 | NUTLIN 3 | authKW | 570706 | 3% | 64% | 72 |
5 | HDM2 | authKW | 535418 | 3% | 54% | 79 |
6 | P53 | authKW | 525642 | 36% | 5% | 874 |
7 | NUTLIN | authKW | 399006 | 2% | 76% | 42 |
8 | HDMX | authKW | 253127 | 1% | 88% | 23 |
9 | P53 MDM2 INTERACTION | authKW | 139957 | 1% | 75% | 15 |
10 | MDM2 INHIBITOR | authKW | 121916 | 1% | 70% | 14 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Cell Biology | 13425 | 38% | 0% | 937 |
2 | Oncology | 10251 | 34% | 0% | 839 |
3 | Biochemistry & Molecular Biology | 5956 | 42% | 0% | 1033 |
4 | Genetics & Heredity | 1474 | 11% | 0% | 280 |
5 | Chemistry, Medicinal | 1071 | 7% | 0% | 169 |
6 | Biophysics | 286 | 5% | 0% | 123 |
7 | Pathology | 140 | 3% | 0% | 70 |
8 | Hematology | 102 | 3% | 0% | 69 |
9 | Developmental Biology | 101 | 2% | 0% | 41 |
10 | Medicine, Research & Experimental | 38 | 3% | 0% | 67 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | P53 | 136513 | 1% | 37% | 30 |
2 | MCARDLE CANC 207A | 49765 | 0% | 100% | 4 |
3 | STATE KAY MOL REACT DYNAM | 49765 | 0% | 100% | 4 |
4 | CRUK SIGNAL TRANSDUCT GRP P53 | 40711 | 0% | 55% | 6 |
5 | ROCHE | 30109 | 1% | 12% | 21 |
6 | BARRY ASHBEE LEUKEMIA S | 24883 | 0% | 100% | 2 |
7 | BIOL CELLULAR MOL PHARMACOL | 24883 | 0% | 100% | 2 |
8 | EDINBURGH CHEM BIOL | 24883 | 0% | 100% | 2 |
9 | IFOM JOINT P53 | 24883 | 0% | 100% | 2 |
10 | INSERM UNITE 940 | 24883 | 0% | 100% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY SERIES | 20335 | 4% | 2% | 90 |
2 | ONCOGENE | 18166 | 7% | 1% | 163 |
3 | CELL DEATH AND DIFFERENTIATION | 3974 | 1% | 1% | 32 |
4 | MOLECULAR CANCER RESEARCH | 3797 | 1% | 1% | 24 |
5 | MOLECULAR AND CELLULAR BIOLOGY | 3200 | 3% | 0% | 77 |
6 | CURRENT CANCER DRUG TARGETS | 2539 | 1% | 1% | 14 |
7 | CANCER CELL | 2056 | 1% | 1% | 16 |
8 | MOLECULAR CANCER THERAPEUTICS | 2023 | 1% | 1% | 26 |
9 | ONCOTARGET | 1891 | 2% | 0% | 44 |
10 | CELL CYCLE | 1874 | 0% | 2% | 10 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | MDM2 | 2875951 | 25% | 38% | 609 | Search MDM2 | Search MDM2 |
2 | MDMX | 1219435 | 4% | 91% | 108 | Search MDMX | Search MDMX |
3 | MDM4 | 590394 | 3% | 77% | 62 | Search MDM4 | Search MDM4 |
4 | NUTLIN 3 | 570706 | 3% | 64% | 72 | Search NUTLIN+3 | Search NUTLIN+3 |
5 | HDM2 | 535418 | 3% | 54% | 79 | Search HDM2 | Search HDM2 |
6 | P53 | 525642 | 36% | 5% | 874 | Search P53 | Search P53 |
7 | NUTLIN | 399006 | 2% | 76% | 42 | Search NUTLIN | Search NUTLIN |
8 | HDMX | 253127 | 1% | 88% | 23 | Search HDMX | Search HDMX |
9 | P53 MDM2 INTERACTION | 139957 | 1% | 75% | 15 | Search P53+MDM2+INTERACTION | Search P53+MDM2+INTERACTION |
10 | MDM2 INHIBITOR | 121916 | 1% | 70% | 14 | Search MDM2+INHIBITOR | Search MDM2+INHIBITOR |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | WADE, M , LI, YC , WAHL, GM , (2013) MDM2, MDMX AND P53 IN ONCOGENESIS AND CANCER THERAPY.NATURE REVIEWS CANCER. VOL. 13. ISSUE 2. P. 83-96 | 118 | 69% | 283 |
2 | KARNI-SCHMIDT, O , LOKSHIN, M , PRIVES, C , (2016) THE ROLES OF MDM2 AND MDMX IN CANCER.ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11. VOL. 11. ISSUE . P. 617 -644 | 149 | 75% | 6 |
3 | MEEK, DW , (2015) REGULATION OF THE P53 RESPONSE AND ITS RELATIONSHIP TO CANCER.BIOCHEMICAL JOURNAL. VOL. 469. ISSUE . P. 325 -346 | 146 | 53% | 45 |
4 | NAG, S , ZHANG, X , SRIVENUGOPAL, KS , WANG, MH , WANG, W , ZHANG, R , (2014) TARGETING MDM2-P53 INTERACTION FOR CANCER THERAPY: ARE WE THERE YET?.CURRENT MEDICINAL CHEMISTRY. VOL. 21. ISSUE 5. P. 553 -574 | 175 | 59% | 25 |
5 | ZHAO, YJ , AGUILAR, A , BERNARD, D , WANG, SM , (2015) SMALL-MOLECULE INHIBITORS OF THE MDM2-P53 PROTEIN-PROTEIN INTERACTION (MDM2 INHIBITORS) IN CLINICAL TRIALS FOR CANCER TREATMENT.JOURNAL OF MEDICINAL CHEMISTRY. VOL. 58. ISSUE 3. P. 1038 -1052 | 65 | 88% | 68 |
6 | CARR, MI , JONES, SN , (2016) REGULATION OF THE MDM2-P53 SIGNALING AXIS IN THE DNA DAMAGE RESPONSE AND TUMORIGENESIS.TRANSLATIONAL CANCER RESEARCH. VOL. 5. ISSUE 6. P. 707 -724 | 159 | 62% | 0 |
7 | LESLIE, PL , ZHANG, Y , (2016) MDM2 OLIGOMERS: ANTAGONIZERS OF THE GUARDIAN OF THE GENOME.ONCOGENE. VOL. 35. ISSUE 48. P. 6157 -6165 | 104 | 82% | 1 |
8 | LEMOS, A , LEAO, M , SOARES, J , PALMEIRA, A , PINTO, M , SARAIVA, L , SOUSA, ME , (2016) MEDICINAL CHEMISTRY STRATEGIES TO DISRUPT THE P53-MDM2/MDMX INTERACTION.MEDICINAL RESEARCH REVIEWS. VOL. 36. ISSUE 5. P. 789 -844 | 118 | 70% | 1 |
9 | HOE, KK , VERMA, CS , LANE, DP , (2014) DRUGGING THE P53 PATHWAY: UNDERSTANDING THE ROUTE TO CLINICAL EFFICACY.NATURE REVIEWS DRUG DISCOVERY. VOL. 13. ISSUE 3. P. 217 -236 | 119 | 52% | 58 |
10 | HOCK, AK , VOUSDEN, KH , (2014) THE ROLE OF UBIQUITIN MODIFICATION IN THE REGULATION OF P53.BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. VOL. 1843. ISSUE 1. P. 137 -149 | 129 | 50% | 42 |
Classes with closest relation at Level 1 |